

Cytarabine

NOT RECOMMENDED AS AN

ESSENTIAL MEDICINE

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc

ATC codes: L01BC01

Indication	Unspecified malignant neoplasms of ill-defined or unspecified sites	ICD11 code: 2D9Z
INN	Cytarabine	
Medicine type	Chemical agent	
List type	Complementary (EML) (EMLc)	
Formulations	Parenteral > General injections > unspecified: 100 mg in vial powder for injection	
EML status history	First added in 1979 (TRS 641) Changed in 2002 (TRS 914) Changed in 2007 (TRS 950) Removed in 2015 (TRS 994)	
Sex	All	
Age	Also recommended for children	
Therapeutic alternatives	The recommendation is for this specific medicine	
Patent information	Patents have expired in most jurisdictions Read more about patents .	↗
Wikipedia	Cytarabine	↗
DrugBank	Cytarabine	↗

Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of cytarabine was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for cytarabine for more information.

